R&D From phase 1 to phase 3: Scaling radiopharmaceutical trials Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.
R&D Why the best CROs challenge the trial plan and keep challeng... Too often, oncology trials fail for reasons that could have been anticipated and addressed.
Patients Why “rare disease” is a regulatory label, not a patient real... Regulators define a rare disease by how many people have it, and the answer depends on who is counting.
R&D Sponsored Beyond recruitment: Creating patient engagement that lasts In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.
R&D Sponsored Turning recruitment potential into enrolment reality In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs
R&D How AI simulation could help de-risk obesity and cardiometab... AI life sciences models allow researchers to explore different patient populations, protocols, and development strategies before a study starts.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.